Healthy Living Europe
SEE OTHER BRANDS

Keeping up with healthcare and wellness news from Europe

Healthy Living Europe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.

Press releases published on May 20, 2025

TrialWire the AI and Algorithm-powered Platform Named a Fierce CRO Award Finalist in the “Outstanding Patient Recruitment and Retention” Category

TrialWire the AI and Algorithm-powered Platform Named a Fierce CRO Award Finalist in the “Outstanding Patient Recruitment and Retention” Category

SAN FRANCISCO, May 20, 2025 (GLOBE NEWSWIRE) -- TrialWire today announces it was named a Fierce CRO Award finalist by Fierce Biotech in the Outstanding Patient Recruitment and Retention category. TrialWire is the AI and algorithm-powered patient- …

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB+, with a stable outlook; from BB. Fitch's report cites …

Neuphoria Provides First Quarter 2025 Business Updates

Neuphoria Provides First Quarter 2025 Business Updates

Cash runway into Q3 2026 AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025 α7 nicotinic acetylcholine receptor PAM MK-1167 partnered with Merck and in Phase 2 clinical trial in Alzheimer’s …

XWELL Reports First Quarter 2025 Results, Advancing Mission to Liberate Science-Proven Wellness

XWELL Reports First Quarter 2025 Results, Advancing Mission to Liberate Science-Proven Wellness

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a pioneer in science-proven, accessible wellness, today reported results for the first quarter ended March 31, 2025. With a growing portfolio of in-airport …

CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet

CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet

SAN RAMON, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (“Cooper”) (Nasdaq: COO), a leading medical device company, published its 2024 Sustainability Report. The report showcases the company’s initiatives to foster positive change for both …

GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l’approbation du prix et du remboursement d’Iqirvo® par Ipsen en Italie

GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l’approbation du prix et du remboursement d’Iqirvo® par Ipsen en Italie

Lille (France), Cambridge (Massachusetts, Etats-Unis), Zurich (Suisse), le 20 mai, 2025 – GENFIT (Nasdaq et Euronext : GNFT), société́ biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares …

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today …

RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum

RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum

ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate …

Amerigo Scientific Introduces Electrospun Polycaprolactone Scaffolds for 3D Cell Culture

Amerigo Scientific Introduces Electrospun Polycaprolactone Scaffolds for 3D Cell Culture

Amerigo Scientific has unveiled its 3D electrospun polycaprolactone (PCL) scaffolds tailored for 3D cell culture applications. NEW YORK, NY, UNITED STATES, May 20, 2025 /⁨EINPresswire.com⁩/ -- Amerigo Scientific has unveiled its 3D electrospun …

Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference

Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference

SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane …

INVO Fertility Announces First Quarter 2025 Financial Results

INVO Fertility Announces First Quarter 2025 Financial Results

SARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and …

Tactile Medical to Present at Upcoming Investor Conferences in June

Tactile Medical to Present at Upcoming Investor Conferences in June

MINNEAPOLIS, May 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will be …

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with…

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with…

REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development …

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers …

Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025

Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025

Topline results for AP02 (inhaled nintedanib) confirmed safety and tolerability with limited systemic exposure and substantially improved lung exposure compared to oral nintedanib AP01 (inhaled pirfenidone) treatment demonstrated long-term antifibrotic …

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant …

pRxEngage Launches to Revolutionize Clinical Trial Access and Engagement

pRxEngage Launches to Revolutionize Clinical Trial Access and Engagement

New Platform Aims to Remove Barriers and Restore Trust in Clinical Trials Through Simplicity and Transparency LONDON, UNITED KINGDOM, May 20, 2025 /⁨EINPresswire.com⁩/ -- pRxEngage, a groundbreaking platform designed to transform how clinical trials …

Healthcare Saas Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034

Healthcare Saas Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034

The Business Research Company's Healthcare Saas Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, May 20, 2025 /⁨EINPresswire.com⁩/ -- The Business Research Company’s Latest Report Explores …

Global Poultry Disinfectant Market To Reach $7.78 Billion By 2029 With A Growth Rate Of 11.1%

Global Poultry Disinfectant Market To Reach $7.78 Billion By 2029 With A Growth Rate Of 11.1%

The Business Research Company’s Poultry Disinfectant Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, May 20, 2025 /⁨EINPresswire.com⁩/ -- Would you believe that the poultry disinfectant …

Global Healthcare Consulting Services Market Forecast: Key Growth Drivers, Trends, and Opportunities from 2025 to 2034

Global Healthcare Consulting Services Market Forecast: Key Growth Drivers, Trends, and Opportunities from 2025 to 2034

The Business Research Company's Healthcare Consulting Services Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, May 20, 2025 /⁨EINPresswire.com⁩/ -- In essence, the healthcare …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service